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Astaxanthin prevents and reverses 
diet-induced insulin resistance 
and steatohepatitis in mice: A 
comparison with vitamin E
Yinhua Ni1,2, Mayumi Nagashimada1, Fen Zhuge1, Lili Zhan1, Naoto Nagata1, 
Akemi Tsutsui3, Yasuni Nakanuma3, Shuichi Kaneko2 & Tsuguhito Ota1,2
Hepatic insulin resistance and nonalcoholic steatohepatitis (NASH) could be caused by excessive 
hepatic lipid accumulation and peroxidation. Vitamin E has become a standard treatment for 
NASH. However, astaxanthin, an antioxidant carotenoid, inhibits lipid peroxidation more potently 
than vitamin E. Here, we compared the effects of astaxanthin and vitamin E in NASH. We first 
demonstrated that astaxanthin ameliorated hepatic steatosis in both genetically (ob/ob) and high-
fat-diet-induced obese mice. In a lipotoxic model of NASH: mice fed a high-cholesterol and high-fat 
diet, astaxanthin alleviated excessive hepatic lipid accumulation and peroxidation, increased the 
proportion of M1-type macrophages/Kupffer cells, and activated stellate cells to improve hepatic 
inflammation and fibrosis. Moreover, astaxanthin caused an M2-dominant shift in macrophages/
Kupffer cells and a subsequent reduction in CD4+ and CD8+ T cell recruitment in the liver, which 
contributed to improved insulin resistance and hepatic inflammation. Importantly, astaxanthin 
reversed insulin resistance, as well as hepatic inflammation and fibrosis, in pre-existing NASH. 
Overall, astaxanthin was more effective at both preventing and treating NASH compared with 
vitamin E in mice. Furthermore, astaxanthin improved hepatic steatosis and tended to ameliorate 
the progression of NASH in biopsy-proven human subjects. These results suggest that astaxanthin 
might be a novel and promising treatment for NASH.
Non-alcoholic fatty liver disease (NAFLD) and insulin resistance coexist frequently in subjects with obe-
sity and type 2 diabetes1,2, and affect 20–30% of the general population and 70–80% of obese and diabetic 
subjects3. It has become increasingly evident that hepatic inflammation and/or fibrosis could be caused 
by excessive hepatic lipid accumulation followed by lipid peroxidation. This ectopic fat or lipotoxicity in 
the liver induces an innate immune response with the subsequent recruitment of immune cells such as 
macrophages and T cells, which leads to the development of insulin resistance and NASH4. Previously, 
we developed a cholesterol- and saturated fatty acid-induced model of lipotoxic NASH that replicated the 
pathophysiological features of human NASH successfully, and found that excessive hepatic lipid accumu-
lation promoted the activation of macrophages/Kupffer cells to exacerbate insulin resistance and hepatic 
inflammation and fibrogenesis5.
Although both insulin resistance and oxidative stress are pivotal for the progression of NASH, no 
standard therapy for NASH has been established4,6. Many agents have been tested for the management 
of NASH, with disappointing results, the antioxidant vitamin E is somewhat efficacious. In the largest 
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randomized controlled trial performed to date, the PIVENS trial demonstrated that vitamin E reduced 
hepatic steatosis and lobular inflammation in adult patients with NASH7. However, there is a continuing 
need for additional and more effective therapies for patients with NASH.
Micronutrient antioxidants, such as vitamins and carotenoids, are depleted severely in the serum 
and liver tissue of patients with chronic liver diseases and cirrhosis8,9. Meanwhile, elevated alanine ami-
notransferase (ALT) levels were associated with decreased antioxidant, particularly carotenoids such as 
α - and β -carotene, and lutein levels in a large population-based study10. More recently, it was reported 
that plasma vitamin E and carotenoid levels were decreased in patients with NASH11. Importantly, carot-
enoids inhibit lipid peroxidation as potently as does vitamin E12,13, but carotenoid supplementation has 
not been used widely as an antioxidant therapy for the treatment of NASH. Recently, we have shown that 
β -cryptoxanthin, an antioxidant carotenoid, inhibits the progression of NASH in mice14,15. However, the 
effects of carotenoid compared with vitamin E are still not clear.
Astaxanthin is a xanthophyll carotenoid found in marine organisms, including salmon, shrimp, crusta-
ceans, and algae such as Haematococcus pluvialis16. Astaxanthin inhibits lipid peroxidation 100–500-fold 
more strongly than vitamin E in vitro17, and has several-fold greater free radical antioxidant activity than 
do vitamin E and β -carotene18. The administration of astaxanthin inhibits carbon tetrachloride-induced 
lipid peroxidation in the rat liver19, and suppresses the upregulation of fibrogenic genes in hepatic stel-
late cells (HSCs) by blocking TGF-β /Smad3 signaling20. In addition, astaxanthin prevents diet-induced 
obesity and hepatic steatosis in mice21 and ameliorates insulin resistance by protecting myocytes from 
oxidative stress22.
Therefore, we hypothesized that the administration of astaxanthin would inhibit the progression of 
NASH by suppressing lipotoxicity-induced oxidative stress and the subsequent lipid peroxidation and 
insulin resistance. Here, the preventative and therapeutic effects of astaxanthin and vitamin E in a lipo-
toxic model of NASH were compared. The data revealed that astaxanthin prevented and reversed hepatic 
insulin resistance and NASH similarly or more potently than did vitamin E by regulating macrophage 
and T-cell accumulation as well as the M1/M2 status of macrophages/Kupffer cells in the liver of mice. 
Furthermore, astaxanthin alleviated the progression of NASH in humans.
Results
Astaxanthin Alleviated Hepatic Steatosis in Obese Mice and Decreased Lipid Accumulation 
in Hepatocytes. To assess the effect of astaxanthin on hepatic steatosis, high-fat diet (HFD)-induced 
obese (DIO) and genetically obese (ob/ob) mice were treated with astaxanthin. Figure  1a shows the 
chemical structure of astaxanthin. After 10 weeks of feeding, astaxanthin administration reduced hepatic 
steatosis and triglyceride (TG) accumulation significantly in both DIO and ob/ob mice, even though 
weight and adiposity were not affected by astaxanthin (Fig. 1b,d). To further clarify the effect of astax-
anthin on lipid accumulation in vitro, primary hepatocytes were incubated with either astaxanthin or 
α -tocopherol, a lipophilic antioxidant that is efficacious when used to treat NAFLD, in the presence of 
oleic acid. Incubation with astaxanthin, but not α -tocopherol, resulted in dose-dependent decrease in 
TG accumulation, as assessed by Oil Red O staining and the cellular TG content in lipid-loaded primary 
hepatocytes (Fig. 1e). Next, quantitative real-time PCR (qPCR) analysis was performed to elucidate the 
mechanism by which astaxanthin decreased lipid accumulation in hepatocytes (Fig. S1a). Astaxanthin 
treatment did not affect the mRNA levels of lipogenic and fatty acid oxidation genes, while expres-
sion of Cd36, a key regulator of lipid uptake, was increased significantly by oleic acid treatment, and 
decreased by astaxanthin in a dose-dependent manner (Fig. S1a). Moreover, the phosphorylation levels 
of p38 MAPK and c-Jun in oleic-acid-loaded hepatocytes were unaffected by astaxanthin (Fig. S1b). To 
assess whether the attenuation of lipid accumulation by astaxanthin is associated with protection against 
lipotoxicity, hepatocytes were co-incubated with palmitic acid and astaxanthin. However, astaxanthin 
had little effect on apoptosis, as assessed by cleavage of caspase-3, and viability in palmitic acid-loaded 
hepatocytes (Fig. S2). Taken together, these results suggest that astaxanthin reduced lipid accumulation 
by decreasing lipid uptake, and therefore improved simple fatty liver.
Astaxanthin Improved Dyslipidemia and Liver Dysfunction in a NASH Model. To determine 
the most effective doses of astaxanthin on diet-induced NASH, C57BL/6J mice were fed different diets 
for 12 weeks (normal chow [NC], NC containing 0.0067% or 0.02% astaxanthin, high-fat, cholesterol, 
and cholate diet [CL], or CL containing 0.0067% or 0.02% astaxanthin). Treatment with astaxanthin 
ameliorated liver pathology and decreased plasma aspartate aminotransferase (AST) and ALT levels in 
diet-induced NASH in a dose-dependent manner (Fig. S3a and S3b). Astaxanthin accumulated in var-
ious tissues after consumption of the CL diet containing 0.02% (w/w) of this material (Fig. S3c); the 
astaxanthin concentrations were higher in the spleen, heart, and liver than in other tissues, suggesting 
that astaxanthin accumulates in the liver and ameliorates NASH. The effects were more prominent in 
the 0.02% astaxanthin-treated group; therefore, subsequent experiments were performed using that dose 
(named the CL+ AX group).
Next, we compared the effects of astaxanthin and vitamin E as similar lipophilic antioxidants on the 
prevention of NASH. The metabolic parameters of mice after 12 weeks on the CL diet are shown in 
Table 1. Astaxanthin decreased plasma TG, total cholesterol (TC), non-esterified fatty acid (NEFA), AST, 
and ALT levels significantly in CL mice. In contrast, vitamin E tended to decrease TG and TC levels, but 
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did not affect NEFA, ALT, and AST levels. Bodyweight, food intake, and liver weight were unaffected 
by astaxanthin or vitamin E in both NC and CL mice. These results suggest that astaxanthin improved 
dyslipidemia and liver dysfunction in NASH mice.
Figure 1. Astaxanthin reduced hepatic steatosis in DIO and ob/ob mice and decreased lipid 
accumulation in vitro. (a) The chemical structure of astaxanthin. (b) The body weights and tissue weights 
of mice (n = 5–8). NT, no treatment; AX, astaxanthin treatment. (c) Representative hematoxylin and eosin 
(H&E)-stained liver sections. Scale bars = 100 μ m. (d) Hepatic TG content (n = 5–8). *P < 0.05 vs. control 
group. (e) Oil Red O staining of cultured primary hepatocytes and cellular TG levels (n = 6). *P < 0.01, vs. 
control incubation; #P < 0.05, ##P < 0.01 vs. oleic acid (OA)-treated cells.
www.nature.com/scientificreports/
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Astaxanthin Prevented the Development of Hepatic Steatosis by Suppressing Lipogenic 
Gene Expression. Mice in each group had similar bodyweights (Fig.  2a) and consumed similar 
quantities of food (Table 1). However, liver size was increased significantly by CL diet feeding, and was 
unaffected by astaxanthin and vitamin E administration (Fig. 2b). Histological analysis revealed severe 
lipid accumulation in the livers of CL mice, which was decreased markedly by astaxanthin and decreased 
NC NC+AX NC+VE CL CL+AX CL+VE
Body weight (g) 32.2 ± 0.6 33.4 ± 0.6 31.6 ± 0.8 34.0 ± 1.0 33.1 ± 0.6 34.6 ± 0.7
Food intake (g/day/kg BW) 86.9 ± 4.7 89.5 ± 4.9 89.4 ± 3.6 75.6 ± 1.7 80.0 ± 1.5 75.7 ± 3.2
Liver weight ratio (%) 3.6 ± 0.3 3.8 ± 0.3 3.9 ± 0.1 5.0 ± 0.1** 4.8 ± 0.1** 4.9 ± 0.1**
Plasma TG (mg/dL) 96.0 ± 4.5 86.8 ± 4.0 111.3 ± 6.3 43.4 ± 3.1** 32.0 ± 2.8**# 33.8 ± 4.8**
Plasma TC (mg/dL) 96.9 ± 3.8 92.3 ± 2.6 93.1 ± 5.0 154.2 ± 3.8** 122.2 ± 4.5**# 137.3 ± 4.1**
Plasma NEFA (mEq/L) 1.34 ± 0.13 1.23 ± 0.10 1.29 ± 0.12 0.98 ± 0.07 0.62 ± 0.09**## 0.92 ± 0.05*
Plasma AST (IU/L) 16.7 ± 5.6 13.6 ± 1.1 18.4 ± 3.3 43.5 ± 2.3** 31.6 ± 2.9**# 43.7 ± 0.4**
Plasma ALT (IU/L) 5.5 ± 1.3 4.8 ± 0.4 5.4 ± 1.8 18.8 ± 1.5** 10.8 ± 0.8**## 17.3 ± 0.4**
Table 1.  Effects of astaxanthin (AX) and vitamin E (VE) on metabolic parameters after 12 weeks 
of treatment. Data were obtained from 20-week-old fasted mice that had been fed different diets. Data 
are presented as means ± SEM (n = 5 for the NC, NC + AX, and NC + VE groups, and n = 8 for the CL, 
CL + AX, and CL + VE groups). *P < 0.05, **P < 001 vs. mice fed normal chow (NC); #P < 0.05, ##P <  0.01 
vs. mice fed CL diet.
Figure 2. Astaxanthin prevented the development of hepatic steatosis in NASH mice. (a) Weight gain 
in mice. (b) Representative photographs of liver. Scale bars = 1 cm. (c) Representative H&E-stained liver 
sections. Scale bars = 100 μ m. (d) Hepatic TG, TC, NEFA, and TBARS contents (n = 5–8). *P < 0.05, 
**P < 0.01 vs. the NC diet; #P < 0.05, ##P < 0.01 vs. the CL-diet-fed group. (e) mRNA expression of lipogenic 
and fatty acid oxidation genes in the livers of mice (n = 8). *P < 0.05, **P < 0.01 vs. the CL group.
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slightly by vitamin E at 20 weeks of age (Fig. 2c). Consistent with these histological findings, CL mice 
exhibited significantly increased hepatic TG, TC, and NEFA levels compared with NC-fed mice, whereas 
astaxanthin administration reduced lipid accumulation significantly in the CL group (Fig. 2d). However, 
vitamin E treatment did not reduce hepatic lipid levels. The levels of thiobarbituric acid reactive sub-
stances (TBARS), an index of lipid peroxidation and oxidative stress, in the liver were increased by the 
CL diet feeding, revealing exaggerated lipid peroxidation in the livers of NASH mice. Both astaxanthin 
and vitamin E treatment decreased hepatic lipid peroxidation (Fig. 2d).
During the development of steatohepatitis, the expression of lipogenic regulator genes, including 
Srebp1c, Lxra, Chrebp, and fatty acid synthesis genes, including Fasn and Scd1, was increased significantly 
in the livers of CL compared with NC mice (Fig. 2e, Fig. S4a). Treatment with astaxanthin suppressed the 
expression of these lipogenic genes, whereas vitamin E did not alter or slightly decreased gene expres-
sion (Fig.  2e). By contrast, astaxanthin had little effect on the expression of genes related to fatty acid 
oxidation, whereas vitamin E administration increased the expression of Ppara and Lcad in CL mice 
(Fig. 2e, Fig. S4a). On the other hand, the upregulated expression of Cd36 by CL diet was downregulated 
by astaxanthin, and unaffected by vitamin E (Fig.  2e, Fig. S4a). These results suggest that astaxanthin 
suppressed lipogenesis and lipid uptake to reduce lipid accumulation in the liver of NAFLD/NASH mice.
Astaxanthin Improved Glucose Intolerance and Insulin Resistance. To determine whether 
astaxanthin affected glucose tolerance or insulin resistance in NASH mice, glucose tolerance tests (GTTs) 
and insulin tolerance tests (ITTs) were performed (Fig.  3). GTTs indicated that the administration of 
astaxanthin decreased blood glucose levels at 180 min in NC-fed mice, whereas vitamin E had no effect 
(Fig.  3a). However, CL diet-induced glucose intolerance and hyperinsulinemia in both the fasting and 
fed states were suppressed significantly by astaxanthin (Fig.  3b,c). Vitamin E treatment also reduced 
plasma insulin levels. ITTs demonstrated that CL+ AX mice had slightly increased insulin sensitivity 
compared with CL mice (Fig. 3d). These results were associated with enhanced insulin-stimulated phos-
phorylation of the insulin receptor (IR)-β subunit (p-IRβ ), and Akt (p-Akt) in the livers of CL+ AX 
mice compared with CL mice, whereas vitamin E had little effect on hepatic insulin signaling (Fig. 3e). 
Furthermore, insulin signaling was enhanced by astaxanthin in palmitic-acid-loaded primary hepat-
ocytes (Fig. S5a). At the cellular level, palmitic-acid-induced insulin resistance was associated with a 
pro-inflammatory response, such as increased phosphorylation of p38 MAPK, NF-κ B p65 and ERK. 
These pro-inflammatory signals were slightly decreased by astaxanthin treatment (Fig. S5b). Therefore, 
astaxanthin protected mice against diet-induced hepatic insulin resistance and glucose intolerance.
Astaxanthin Reduced the Activation of Both Kupffer and Stellate Cells and Attenuated 
Hepatic Inflammation and Fibrosis. We confirmed previously that the number of F4/80+ mac-
rophages/Kupffer cells was increased significantly in the livers of CL mice, suggesting that the CL diet 
induced intense inflammation in the liver5. Astaxanthin and vitamin E treatment markedly and slightly 
reduced the number of F4/80+ cells, respectively, as assessed by immunostaining and the analysis of 
mRNA expression (Fig.  4a,b). In addition, astaxanthin decreased the expression of proinflammatory 
cytokines, including Tnf, Il6, and Il1b, which were upregulated by the CL diet, to extents greater than did 
vitamin E (Fig. 4b, Fig. S4b). These findings were also associated with the attenuated phosphorylation of 
JNK, p38 MAPK, and NF-κ B p65 (Fig. 4c). Therefore, astaxanthin reduced the infiltration and activation 
of Kupffer cells to attenuate hepatic inflammation in NASH mice.
Histological analyses using Azan and Sirius Red staining revealed that the CL diet alone induced 
fibrosis, as described previously5. Astaxanthin prevented the development of hepatic fibrosis (Fig.  4a). 
In addition, hydroxyproline content, a biochemical marker of hepatic collagen content, increased signif-
icantly in CL mice vs. NC mice. Importantly, astaxanthin lowered the hydroxyproline content signifi-
cantly, whereas vitamin E had only a small effect (Fig. 4d). Immunohistochemical staining for α -SMA 
showed that the CL diet-induced increase in α -SMA-positive HSC numbers was markedly decreased by 
astaxanthin (Fig. 4a), and slightly by vitamin E; these observations were confirmed by immunoblotting 
and qPCR (Fig. 4d,e). In addition, astaxanthin inhibited the increased expression of the fibrogenic genes 
Tgfb1, Col1a1, and PAI-1 caused by consumption of the CL diet, whereas vitamin E suppressed PAI-1 
mRNA expression (Fig.  4e, Fig. S4c). Combined, these results suggest that astaxanthin decreased the 
accumulation of collagen by inhibiting the activation of HSCs in the liver, thereby attenuating hepatic 
fibrosis.
Reciprocal Decrease in M1-type Macrophages and Increase in M2-type Macrophages in the 
Livers of Astaxanthin-fed Mice. To further quantify hepatic macrophage subsets, FACS was used to 
analyze macrophages/Kupffer cells isolated from mice (Fig. S6). Consistent with the results of immuno-
histochemistry, the total number of hepatic macrophages increased by 1.9-fold in mice fed the CL diet 
compared with the NC diet (Fig. S7a and S7b). However, CL+ AX mice exhibited a slightly decreased 
total macrophage content compared with CL and CL+ VE mice (Fig.  5a,b). Specifically, CL+ AX and 
CL+ VE mice exhibited a 56% and 33% reduced CD11c+ CD206− (M1-type) macrophage count, respec-
tively, whereas the number of CD11c− CD206+ (M2-type) macrophages was increased by 3.7- and 
1.5-fold, respectively. In addition, the percentage of M1-type and M2-type macrophages was decreased 
and increased significantly, respectively, by both astaxanthin and vitamin E treatment (Fig.  5b). These 
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effects resulted in a predominance of M2 rather than M1 macrophage population in the livers of both 
astaxanthin- and vitamin E-fed mice (Fig.  5c). These results were associated with a reduction in the 
expression of M1 macrophage markers (Cd11c, iNOS, Mcp1, and Ccr2) and an increase in the expression 
of M2 macrophage markers (Cd163, Cd206, Il10, Chi3l3, and Mgl1) mRNA expression (Fig. 5d, Fig. S4d). 
However, a predominance of a Ly6C− over Ly6Chi monocyte population was not observed in either the 
peripheral blood or bone marrow of CL+ AX and CL+ VE mice (Fig. S7c and S7d). This suggests that 
astaxanthin and vitamin E caused a dynamic shift to an M2-dominant macrophage phenotype in the 
livers of NASH mice.
Since T cells are involved in the pathogenesis of NASH, we next assessed the effects of astaxan-
thin and vitamin E on T cell recruitment. The total number of CD3+, CD4+, and CD8+ T cells in the 
liver was increased significantly by CL diet feeding (Fig. S7e), and decreased by either astaxanthin (by 
50%, 54%, and 52%, respectively) or vitamin E (43%, 54%, and 40%) (all P < 0.05; Fig. 5e,f). Therefore, 
astaxanthin and vitamin E suppressed the accumulation of helper and cytotoxic T cells. In addition, 
astaxanthin (25–100 μ M) decreased the expression of LPS-induced M1 markers (Tnf, Il1b, and Ccl5) in 
RAW264.7 macrophages, but augmented IL-4-induced M2 marker expression (Il10, Cd209a, and Chi3l3) 
Figure 3. Astaxanthin ameliorated diet-induced glucose intolerance and hepatic insulin resistance. 
(a,b) Glucose tolerance tests (GTTs; n = 5–8). *P < 0.05, **P < 0.01 NC+ AX group vs. NC group or 
CL+ AX group vs. CL group. (c) Plasma insulin levels (n = 5–8). *P < 0.05 vs. mice fed a NC diet; #P < 0.05, 
##P < 0.01 vs. mice fed a CL diet. (d) Insulin tolerance tests (ITTs) in CL-diet fed mice (n = 8). *P < 0.05 vs. 
CL group. (e) Hepatic insulin signaling (n = 4). *P < 0.05 vs. CL group.
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in a dose-dependent manner (Fig. S8a and S8b). This suggests that astaxanthin improved hepatic insulin 
resistance and inflammation via an M2-dominant shift in macrophages/Kupffer cells and a subsequent 
reduction in T cell accumulation in NASH.
Astaxanthin Reversed Advanced NASH More Potently than Vitamin E in Mice. Next, we com-
pared the therapeutic effects of astaxanthin and vitamin E on advanced-stage NASH in mice. After 
NASH was induced by feeding CL diet for 12 weeks, the CL diet with or without either astaxanthin or 
vitamin E was administered for an additional 12 weeks (Fig. 6a). Treatment with astaxanthin decreased 
plasma TG, TC, NEFA, AST, ALT and insulin levels in CL mice significantly without affecting body 
and liver weight (Table S1), whereas vitamin E treatment had little effect on these metabolic parame-
ters. Astaxanthin significantly improved glucose intolerance and insulin resistance, whereas Vitamin E 
was less effective (Table S1, Fig. S9a and S9b). Histologically, astaxanthin treatment markedly amelio-
rated the macrovascular steatosis, macrophage/Kupffer cell infiltration, and fibrosis associated with HSC 
Figure 4. Astaxanthin attenuated hepatic inflammation and fibrosis in NASH mice. (a) F4/80 
immunostaining, Azan and Sirius Red staining, α -SMA immunostaining; scale bars = 100 μ m. (b) mRNA 
expression of F4/80 and inflammatory cytokines in mouse livers. (c) Immunoblots and quantification of 
p-p38MAPK, p-JNK, and p-NF-κ B p65 levels in the liver. (d) Hydroxyproline content and immunoblotting 
and quantification of α -SMA expression in mouse livers. (e) mRNA expression of fibrogenic genes in the 
livers. n = 5–8, *P < 0.05, **P < 0.01 vs. NC or CL group; #P < 0.05, ##P < 0.01 vs. the CL group.
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activation, but Vitamin E only minimally affected these histological changes (Fig. 6b,d). Potent hepatic 
inflammation, as characterized by increased stress or inflammatory signaling and upregulated inflamma-
tory genes, was attenuated significantly by astaxanthin (Fig. 6e,f). Astaxanthin suppressed fibrogenic gene 
expression markedly, whereas vitamin E decreased hepatic inflammation and fibrogenesis only slightly 
Figure 5. Decreased M1-type and increased M2-type macrophages in NASH livers after astaxanthin 
administration. (a,b) A representative plot and quantitation of M1/M2 macrophages in the livers of 
mice. (c) M1/M2 ratios. (d) mRNA expression of M1 and M2 macrophage markers in the livers. (e,f) A 
representative plot of CD3+ T cells and quantitation of CD3+, CD8+, CD4+ T cells in the livers of mice 
(n = 8). *P < 0.05, **P < 0.01 vs. the CL group, #P < 0.05, CL+ AX group vs. the CL+ VE group.
www.nature.com/scientificreports/
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(Fig. 6f). Together, these results suggest that astaxanthin was more effective at reversing advanced NASH 
than was vitamin E.
Astaxanthin Alleviated NASH in Humans. Since our results revealed promising preventative and 
therapeutic effects of astaxanthin on NASH in mice, we next extended our studies to humans. Twelve 
biopsy-confirmed NASH patients were treated orally with placebo (n = 5) or astaxanthin (n = 7) for a 
total of 24 weeks. The clinical background and plasma parameters of patients are shown in Table S2. After 
24 weeks of astaxanthin treatment, plasma parameters involved in glucose and lipid metabolism and liver 
functions were unaffected by astaxanthin treatment. Moreover, no significant difference was observed in 
the changes from baseline between the placebo- and astaxanthin-treated patients (Table S2). However, 
Figure 6. Astaxanthin reversed advanced NASH in mice. (a) Study design to assess the therapeutic effects 
of astaxanthin and vitamin E. (b) Histological analysis of liver sections; scale bars = 100 μ m. (c) Hepatic TG, 
TC, NEFA, and TBARS levels. (d) Hydroxyproline content (left) and immunoblotting for α -SMA (right) in 
the livers. (e) Immunoblotting and quantification of p-p38MAPK, p-JNK, and p-NF-κ B p65 levels in the 
livers. (f) mRNA expression of inflammatory cytokine and fibrogenic genes in the livers (n = 8). *P < 0.05, 
**P < 0.01 vs. the CL group; #P < 0.05, CL+ AX group vs. CL+ VE group.
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astaxanthin treatment improved hepatic steatosis markedly in NASH patients (Fig. 7a). In addition, pla-
cebo treatment did not affect NAFLD activity score, while astaxanthin treatment reduced the grade of 
steatosis and tended to alleviate lobular inflammation, but did not alter the presence of ballooning or 
the stage of fibrosis (Fig. 7b). Together, these results suggest that astaxanthin reduces the total NAS score 
and alleviates human NASH.
Discussion
This study compared the effects of the potent antioxidant carotenoid astaxanthin and vitamin E on NASH 
and elucidated the potential mechanism underlying the effects. We found that astaxanthin exhibited 
significant preventative and therapeutic effects on NASH in a lipotoxic model. Astaxanthin attenuated 
insulin resistance and excessive hepatic lipid accumulation and peroxidation, an increased propor-
tion of proinflammatory or M1-type macrophages/Kupffer cells, stellate cell activation, and fibrosis in 
diet-induced NASH. In addition, astaxanthin ameliorated simple steatosis, the early stage of NAFLD, in 
both genetically obese (ob/ob) and DIO mice. Finally, we demonstrated that astaxanthin has the potential 
to improve NASH in humans.
The different mechanisms of action determined by comparing astaxanthin and vitamin E in NASH 
mice are intriguing because both of these lipophilic antioxidants suppress hepatic lipid peroxidation to 
an equivalent extent (Fig.  2d). Collectively, these results suggest that astaxanthin is similarly or more 
effective at preventing and treating NASH than is vitamin E (Table S3). First, astaxanthin was superior to 
vitamin E at improving steatosis by suppressing lipid accumulation (Fig. 2). Second, astaxanthin reduced 
inflammation and insulin resistance more potently than did vitamin E. Of note, these anti-inflammatory 
and insulin sensitizing effects were associated with attenuated MAPK (JNK/p38 MAPK) and NF-κ B 
activation (Fig. 4), decreased macrophage/Kupffer cell and T cell accumulation, as well as alternative M2 
macrophage activation in the liver (Fig. 5). Finally, astaxanthin prevented and reversed hepatic fibrosis 
to a greater extent than did vitamin E (Figs 4 and 6).
Hepatic macrophages, which consist of resident Kupffer cells and recruited bone marrow-derived 
macrophages, are the major cells that produce inflammatory mediators such as TNF-α and IL-1β to 
cause systemic insulin resistance as well as NASH23. Tissue macrophages are phenotypically heterogene-
ous: M1 or classically activated macrophages are stimulated by Toll-like receptor ligands such as LPS and 
interferon-gamma, whereas M2 or alternatively activated macrophages are stimulated by IL-4/IL-1324,25. 
The dysregulation of M1/M2 polarization is emerging as a central mechanism underlying the patho-
genesis of chronic inflammation, atherosclerosis, obesity, and comorbidities such as insulin resistance 
and NAFLD24–26. More recently, M2 macrophages/Kupffer cells have been reported to protect against 
alcoholic and nonalcoholic fatty liver disease by promoting M1 macrophage/Kupffer cell apoptosis27. 
Figure 7. Astaxanthin alleviated NASH in humans. (a) Representative H&E-stained liver sections from 
two subjects with NASH before and after treatment revealed that astaxanthin improved steatohepatitis 
after 24 weeks of treatment. Scale bars = 400 μ m for low magnification (upper), and 100 μ m for high 
magnification (lower). (b) NAFLD activity score (NAS) in NASH subjects before and after treatment with 
placebo (n = 5) or astaxanthin (AX, n = 7). *P < 0.05 vs. pretreatment.
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Therefore, strategies that modify macrophage polarization by restraining M1 or driving M2 activation 
might protect against inflammation and insulin resistance, and thereby halt the progression of NASH.
The current in vitro studies (Fig. S8) and FACS data suggested that astaxanthin caused a reciprocal 
decrease in M1 macrophages and increase in M2 macrophages to attenuate insulin resistance and inflam-
mation in NASH. These results were associated with attenuated inflammatory signaling via JNK, as well 
as enhanced insulin signaling in the livers of CL mice (Figs 3e and 4c). This is consistent with a study 
by Han et al., who demonstrated that JNK activation is required for M1 macrophage polarization during 
obesity-associated inflammation and insulin resistance28. T cells are critical regulators of macrophage 
polarization, and some studies have demonstrated that the infiltration of Th1 and CD8+ T cells precedes 
M1-polarized macrophage recruitment and contributes to insulin resistance in response to obesity29. 
Sutti et al. reported that lipid peroxidation induced the liver recruitment of CD4+ and CD8+ T cells, 
which in turn further stimulated a macrophage M1 response in a dietary model of NASH30. Therefore, 
astaxanthin suppressed the recruitment of T cells as well as M1 activation of macrophages to alleviate 
hepatic insulin resistance and the progression of NASH.
An important question is whether astaxanthin affects the M1/M2 status in bone marrow or periph-
eral blood given the link between monocyte subtypes and their fate as M1/M2 macrophages in NASH. 
However, astaxanthin did not affect Ly6Chi or Ly6C− monocyte subsets either in the bone marrow or 
peripheral blood (Fig. S7c and S7d). Instead, consistent with previous studies31, astaxanthin accumulated 
robustly in the livers of mice (Fig. S3c). Furthermore, astaxanthin induced M2 macrophages remarkably 
in vivo (Fig.  5b,c), and also augmented IL-4-induced M2 or the alternative activation of macrophages 
in vitro (Fig. S8b). These data suggest that astaxanthin caused a dynamic shift in the M2 polarization 
of macrophages/Kupffer cells within the liver, which contributed to the attenuation of insulin resistance 
and the progression of NASH.
It is important that the improvements in hepatic steatosis and dyslipidemia caused by astaxanthin were 
not secondary to a reduction in caloric intake, weight, or adiposity. The increased delivery of fatty acids 
to the liver and/or de novo lipogenesis, which are seen commonly in insulin resistance, results in oxida-
tive stress. Our results showed that astaxanthin decreased the expression of lipogenic and lipid-uptake 
genes without affecting genes related to fatty acid oxidation in the liver of NASH mice (Fig. 2e). These 
effects would contribute to both the reduced lipid accumulation and amelioration of hepatic steatosis.
Lipid-induced cellular stresses can induce the innate immune response, insulin resistance, and 
fibrogenesis by activating Kupffer cells and HSCs in the liver5,32. Our data suggest that astaxanthin could 
reduce the associated increased oxidative stress, as shown by the reduced levels of TBARS, and thereby 
inhibit lipid peroxidation and the subsequent development of hepatic insulin resistance, inflammation, 
and fibrosis. Moreover, fatty acid-induced insulin resistance at the hepatocyte level is caused by reactive 
oxygen species (ROS)33. Astaxanthin, probably due to its strong antioxidant effect, decreased ROS gener-
ation and, therefore, improved insulin signaling. In addition, astaxanthin increases Akt phosphorylation, 
which is associated with decreased phosphorylation of ERK in cultured rat muscle cells22. Our results 
also demonstrated that astaxanthin attenuated p38 MAPK and ERK phosphorylation, which contributed 
to the improvement of hepatic insulin resistance.
To date, the molecular targets of vitamin E and carotenoids in NASH remain unclear. A recent 
sub-study of PIVENS demonstrated that the response of NASH to vitamin E treatment was associ-
ated with decreased hedgehog pathway activity34. Meanwhile, the biological actions of carotenoids are 
mediated in part by retinoic acid, an active form of provitamin A. Provitamin A carotenoids such as 
β -carotene and β -cryptoxanthin act via the retinoic acid receptor (RAR) to benefit human health35. By 
contrast, astaxanthin, which is similar to lutein and zeaxanthin, is a non-provitamin A carotenoid that 
cannot be converted to retinoid. However, some studies demonstrated that the actions of astaxanthin are 
mediated via RAR or retinoid signaling36,37. The concentrations of astaxanthin and vitamin E used in this 
study were identical and/or similar to those used in previous works21,38. It is noteworthy that astaxan-
thin exhibited better potential for inhibiting lipotoxicity-induced insulin resistance and NASH than did 
vitamin E. Notably, astaxanthin does not act as a prooxidant, unlike α -lipoic acid and vitamins C and 
E39. Therefore, astaxanthin might act via RAR or other nuclear receptors7,40 to exert effects on NASH 
in addition to its antioxidant effect. Additional studies are needed to better understand the potential 
of astaxanthin in NASH and investigate whether astaxanthin and vitamin E have common or unique 
molecular mechanisms of action. Furthermore, a combination of astaxanthin and vitamin E might exert 
a synergistic effect, improving the prevention or treatment of NASH.
In summary, this study demonstrated that astaxanthin, a potent antioxidant carotenoid, inhibited and 
reversed lipotoxicity-induced insulin resistance and steatohepatitis in mice by attenuating hepatic lipid 
accumulation and peroxidation. The beneficial effects of astaxanthin were attributable in part to both 
the decreased hepatic recruitment of T cells and macrophages, as well as an M2-dominant polarization 
of macrophages/Kupffer cells to attenuate whole-body insulin resistance and hepatic inflammation and 
fibrosis. Astaxanthin was more effective at preventing and treating NASH than was vitamin E in mice. 
Taken together with our preliminary results indicating improvement in human NASH, astaxanthin might 
be a novel and promising treatment for NASH.
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Methods
Mice and Diets. Seven-week-old male C57BL/6J mice and 5-week-old male ob/ob mice were pur-
chased from Charles River Laboratories (Yokohama, Japan). For hepatic steatosis experiments, C57BL/6J 
mice and ob/ob mice were fed normal chow (NC) that contained 10% of calories from fat (CRF-1, 
Charles River) or a high-fat diet (HFD) that provided 60% of calories from fat (Research Diets Inc., 
New Brunswick, NJ, USA) with or without 0.02% astaxanthin (Fuji Chemical Industry Co Ltd, Toyama, 
Japan)22 for 10 weeks. For NASH experiments, the mice were divided into six groups and fed for 12 
weeks as follows: 1, NC; 2, NC containing 0.02% astaxanthin (NC+ AX); 3, NC containing 0.02% vita-
min E (NC+ VE); 4, high-fat, cholesterol, and cholate diet (CL, also referred to as atherogenic high-fat; 
Research Diets; 60% of calories from fat, 1.25% cholesterol, 0.5% sodium cholate)5; 5,CL diet with 0.02% 
astaxanthin (CL+ AX); or 6, CL diet with 0.02% vitamin E (CL+ VE). All mice were maintained on a 
12/12-h light/dark cycle and were given free access to food and water.
All animal procedures were performed in accordance with the standards set forth in the Guidelines 
for the Care and Use of Laboratory Animals at Kanazawa University, Japan. The protocols were approved 
by the Institute for Experimental Animals of Kanazawa University.
Measuring Astaxanthin Concentrations. After 8-week-old C57BL/6J mice had been fed a CL or 
CL+ AX diet for 3 weeks and then fasted for 2 h, tissues were collected and snap-frozen in liquid nitro-
gen. The astaxanthin concentrations in tissues were then measured using HPLC, as described previ-
ously31; data are reported as μ g/g organ.
Lipid, Glucose, and Insulin Determinations. Plasma triglycerides (TG), total cholesterol (TC), 
non-esterified fatty acids (NEFA), AST, ALT, glucose, and insulin levels, and hepatic TG, TC, and NEFA 
concentrations were measured as described previously5,41. Liver thiobarbituric acid reactive substrates 
(TBARS) were extracted and measured according to the instructions provided with the TBARS assay 
kit (Cayman Chemicals, Ann Arbor, MI). All hepatic lipid levels were normalized to liver protein levels.
Glucose tolerance tests (GTTs) was conducted after an overnight fast after 12 weeks of feeding. After 
baseline blood collection, mice were injected intraperitoneally with 2 g/kg glucose. One week later, insu-
lin tolerance tests (ITTs) were performed after a 4-h fast and mice were injected intraperitoneally with 
0.5 U/kg human insulin.
Histological Examination and Immunohistochemistry. Paraffin-wax-embedded liver sections 
were stained with H&E, Azan, and Sirius Red, and immunohistochemistry for F4/80 or α -SMA was 
performed as described previously26,41.
Hydroxyproline Assay. To assess liver collagen content, hydroxyproline levels were measured using 
a spectrophotometric assay, as described previously42. Briefly, liver tissue was homogenized in 1-mL 
ice-cold saline, and the homogenates were incubated on ice for 30 min with 125 μ L of 50% trichloro-
acetic acid. Subsequently, the precipitated pellets were hydrolyzed for 24 h at 110 °C in 6 N HCl, filtered, 
and neutralized with 10 N NaOH. The resulting hydrolysates were then oxidized with chloramine-T 
(Sigma-Aldrich) for 25 min. The reaction mixture was then incubated in Ehrlich’s perchloric acid solu-
tion at 65 °C for 20 min. Finally, the absorbance at 560 nm was measured after samples had been cooled 
to room temperature. The hydroxyproline content was normalized to liver protein levels.
Quantitative Real-Time PCR. Total RNA was isolated from frozen liver samples using a GenElute 
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). cDNA was synthesized using a High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). Quantitative real-time PCR 
(qPCR) was then performed on a CFX384 machine (Bio-Rad, Hercules, CA, USA) using SYBR Green 
Master Mix, as described previously26. The primers used for real-time PCR are shown in Table S4. The 
mRNA expression levels in the groups were normalized to those of NC-fed mice.
Immunoblots. Tissues were homogenized and sonicated in radioimmunoprecipitation assay (RIPA) 
lysis buffer (Millipore, Billerica, MA, USA), supplemented with protease and phosphatase inhibitors 
(Roche Diagnostics). The primary antibodies used were anti-phospho- c-Jun N-terminal kinase (JNK) 
(Thr183/Tyr185; #9255), anti-JNK (#9258), anti-phospho-p38 mitogen-activated protein kinases (p38 
MAPK) (Thr180/Tyr182; #9211), anti-p38 MAPK (#9212), anti-phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Thr204; #9101), anti-ERK1/2 (#9102), anti-phospho-nuclear factor kappa light chain-enhancer 
of activated B cells (NF-κ B) p65 (Ser536; #3033), anti-NF-κ B (#3034), anti-phospho-c-Jun (Ser73; 
#3270), anti-c-Jun (#9165), anti-phospho-insulin receptor β subunit (IR-β ) (Tyr1146; #3021), anti-IR 
β (#3025), anti-phospho-Ser473 serine/threonine protein kinase Akt (Akt; #9271), anti-Akt (#9272), 
caspase-3 (#14220) (all from Cell Signaling Technology [Danvers, MA]), anti-α -SMA (sc-53141) (Santa 
Cruz Biotechnology [Santa Cruz, CA]), and monoclonal anti β -actin (A5441) (Sigma-Aldrich).
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Fluorescence-activated Cell Sorting (FACS) Analysis. The left lobes of the livers were lysed gently 
and digested for 20 min at 37 °C using type IV collagenase (Sigma-Aldrich, St. Louis, MO, USA) and 
type I deoxyribonuclease in PBS containing 2% BSA (pH 7.4). Non-parenchymal cells were incubated 
with Fc Block™ (BD Biosciences, San Jose, CA, USA) and then incubated with fluorochrome-conjugated 
antibodies (Table S5). Cells were analyzed using FACSAria II (BD Bioscience) as described previously26. 
Data analysis and compensation were performed with the aid of FlowJo (Tree Star, Ashland, OR, USA).
Isolation of Primary Hepatocytes and Cell Culture Experiments. Mouse primary hepatocytes 
were isolated from a male C57BL/6J mouse (8–12 weeks) as described previously43. After growth in 
Dulbecco’s modified Eagle’s medium (DMEM, [Gibco, Invitrogen, Carlsbad, CA]) without fetal bovine 
serum (FBS) for 6 h, the cells were treated with 400 μ M oleic acid (Sigma-Aldrich) and astaxanthin (25, 
50, 100 μ M) for 16 h and then harvested. To measure the hepatocyte lipid content, cells were fixed in 
10% formalin for 1 h, washed with 60% isopropanol, and stained with Oil Red O (Sigma-Aldrich) for 
10 min. The cells were then washed repeatedly with water, photographed, and destained using 100% iso-
propanol for 15 min. The optical density of the isopropanol solution was measured at 500 nm. Cellular 
TG levels were measured as described previously32. To examine the effect of astaxanthin on apoptosis 
and cell viability, the cells were serum-starved for 6 h, and then were treated with 400 μ M palmitic acid 
(Sigma-Aldrich) and astaxanthin (25, 50, 100 μ M) for 16 h. Cell Counting Kit-8 (CCK-8) assay (Dojindo 
Laboratories, Kumamoto, Japan) was performed to measure cell viability according to the manufacturer’s 
instructions. To assess insulin signaling, the hepatocytes were pretreated with 400 μ M PA and 100 μ M 
astaxanthin for 16 h, followed by stimulation with 100 nM insulin (Sigma-Aldrich) for 10 min. Mouse 
RAW264.7 macrophages were grown in DMEM supplemented with 10% FBS in a humidified atmosphere 
of 5% CO2 at 37 °C until the cells reached 90% confluence. The cells were then serum-starved for 6 h, and 
co-incubated with 1 μ g/mL lipopolysaccharide (LPS) (Sigma-Aldrich) or 10 ng/mL IL-4 (Sigma-Aldrich) 
and 25, 50, or 100 μ M astaxanthin for 24 h.
Human Liver Samples. Paraffin-embedded human liver tissues were obtained from liver biopsy sam-
ples of patients with NAFLD in a randomized clinical trial performed at Kanazawa University Hospital, 
Japan (UMIN000008524) from March 2012 to September 2013. Patients with serum ALT level over 31 
IU/L, and alcohol intake less than 30 g/day for male, and 20 g/day for female were participated in this 
trial, and orally administrated with 12 mg/day for total 24 weeks. Liver biopsies were conducted before 
and end of the trial, and read by two hepatopathologist who was blinded to clinical data. Liver biopsies 
were scored using the NASH Clinical Research Network Histologic Scoring System44. The NAFLD activ-
ity score (NAS) was calculated as an unweighted sum of the grade of steatosis (0–3), grade of lobular 
inflammation (0–3), and presence of ballooning (0–2). Progressed NASH was regarded as fibrosis stages 
2–4, whereas early NASH was defined as fibrosis stages 0–1. NASH patients were diagnosed histologically 
with an NAFLD activity score (NAS) of ≥ 5 were analyzed in this study. The study was approved by the 
ethics committee of Kanazawa University Hospital, and the methods were carried out in accordance with 
the approved guidelines. Informed consent was collected from each participant according to the protocol 
approved by Kanazawa University Hospital.
Statistical Analysis. All data are presented as means ± SEM. Differences between the mean values 
from two groups were assessed using two-tailed Student’s t-tests. Differences in mean values among more 
than two groups were determined using ANOVA. P values < 0.05 were considered to indicate statistical 
significance.
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